AvKARE Recalls Two Products After Packaging Mix-Up

Article

Due to a packaging error, the company is voluntarily recalling one lot of sildenafil 100 mg tablets for the treatment of erectile dysfunction and one lot of trazodone 100mg tablets for the treatment of major depressive disorder.

FDA announced on Dec. 9, 2020 that AvKARE, a US-based pharmaceutical solutions company, is voluntarily recalling one lot of sildenafil 100 mg tablets for the treatment of erectile dysfunction and one lot of trazodone 100 mg tablets for the treatment of major depressive disorder to the consumer level because of a product mix-up that packaged the two products together during bottling at a third-party facility.

According to an FDA press release, the affected lot of sildenafil was Lot 36884 with an expiration date of March 2022, and the affected lot of trazodone was Lot 36783 with an expiration date of June 2022. The affected drugs were distributed to the company’s distributors and wholesalers, and then further distributed nationwide.

When taken unintentionally, sildenafil can pose serious health risks to those with underlying health conditions because of its tendency to interact with nitrates found in some prescription drugs, which can lower blood pressure to dangerous levels, FDA said in the press release. Additionally, unintended intake of trazodone can lead to somnolence or sedation, dizziness, constipation, and blurred vision. The adverse health consequences from trazodone are often more concerning for elderly patients due to the increased risk for falls and driving impairment.

As of Dec. 9, 2020, AvKAR has not received any reports of adverse events related to the recall.

Source: FDA

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
© 2025 MJH Life Sciences

All rights reserved.